menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Lisata Therapeutics to Present at the Investival Showcase USA

    GLOBENEWSWIRE

    Lisata, GATC Health Partner To Use AI For Drug Development

    GLOBENEWSWIRE

    Lisata Therapeutics Reports 2024 Financial Results and Update

    GLOBENEWSWIRE

    Lisata To Release 2024 Results, Business Update On Feb 27

    GLOBENEWSWIRE

    Lisata Therapeutics to Present at BIO CEO & Investor Conf 2025

    GLOBENEWSWIRE

    Lisata & Warpnine Show Encouraging Results For Certepetide In PDAC

    GLOBENEWSWIRE

    Lisata Therapeutics Reports Ph 2 Data On Certepetide For Cancer

    GLOBENEWSWIRE

    Lisata Therapeutics to Present at 2025 Sequire Investor Summit

    GLOBENEWSWIRE

    Lisata Therapeutics Completes Enrollment in Cendifox Trial

    GLOBENEWSWIRE

    Lisata Therapeutics, Kuva Labs Announce License for Tumor Imaging

    GLOBENEWSWIRE

    Lisata Therapeutics Wins BioTech Breakthrough Award 2024

    GLOBENEWSWIRE

    Lisata Therapeutics Reports Q3 2024 Financial Results & Update

    GLOBENEWSWIRE

    Lisata Therapeutics to Report Q3 2024 Financials & Updates Nov 12

    GLOBENEWSWIRE

    Lisata & Valo Announce Preclinical Research Collaboration

    GLOBENEWSWIRE

    Lisata Therapeutics to Attend Industry & Investor Events in Nov

    GLOBENEWSWIRE

    Lisata Signs Research Agreement on Certepetide for Endometriosis

    #N/A

    Lisata To Join October 2024 Industry And Investor Events

    GLOBENEWSWIRE

    LisataAnnounces Treatment First Patient in BOLSTER Trial Cohort

    GLOBENEWSWIRE

    Lisata Therapeutics To Participate In September Events

    GLOBENEWSWIRE

    Lisata`s Certepetide Granted FDA Orphan Drug Designation

    GLOBENEWSWIRE

    Lisata Therapeutics Reports Q2 2024 Results And Business Update

    GLOBENEWSWIRE

    Lisata Therapeutics To Report Q2 2024 Results On August 12

    GLOBENEWSWIRE

    Haystack And Lisata Partner On Pancreatic Cancer Therapy Evaluation

    GLOBENEWSWIRE

    Lisata Completes Enrollment In Certepetide Cholangiocarcinoma Trial

    GLOBENEWSWIRE

    Lisata`s Certepetide Shows Promise For Intrahepatic Cholangiocarcinoma

    GLOBENEWSWIRE

    Lisata Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

    GLOBENEWSWIRE

    Lisata Therapeutics: Participating In June 2024 Industry, Investor Events

    GLOBENEWSWIRE

    Lisata Receives EMA Paediatric Waiver For Certepetide In Pancreatic Cancer

    GLOBENEWSWIRE

    Lisata Therapeutics Q1 2024 Financials And Business Update

    GLOBENEWSWIRE

    Lisata to Participate in Upcoming May 2024 Industry and Investor Events

    GLOBENEWSWIRE

    Lisata Q1 2024 Results, Business Update On May 9

    GLOBENEWSWIRE

    Lisata and Qilu Treat First Patient in LSTA1 Pancreatic Cancer Trial

    GLOBENEWSWIRE

    Lisata Therapeutics Announces FDA Orphan Drug Designation Granted to LSTA1

    GLOBENEWSWIRE

    Lisata to Participate in Upcoming April 2024 Industry and Investor Events

    GLOBENEWSWIRE

    Lisata clinches rare disease status for osteosarcoma drug

    PHARMACEUTICAL TECHNOLOGY

    Lisata Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1

    GLOBENEWSWIRE

    Lisata Reports Full Year 2023 Financial Results and Provides Business Update

    GLOBENEWSWIRE

    Lisata Therapeutics to Host Year-End 2023 Conference Call

    GLOBENEWSWIRE

    Lisata Therapeutics to Present at BIO CEO & Investor Conference

    GLOBENEWSWIRE

    Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

    GLOBENEWSWIRE

    Lisata Announces First Patient Treated in the Phase 2a Trial of LSTA1

    GLOBENEWSWIRE

    Lisata Announces Publication of Case Report on Patient Treated with LSTA1

    GLOBENEWSWIRE

    Lisata Announces Completion of Enrollment in Phase 2b Trial of LSTA1

    GLOBENEWSWIRE

    Lisata Therapeutics to Present at NobleCon19 Investor Conference

    GLOBENEWSWIRE

    Lisata Therapeutics Announces Participation in Upcoming Conferences in November

    GLOBENEWSWIRE

    Lisata Reports Third Quarter 2023 Financial Results and Provides Business Update

    GLOBENEWSWIRE

    Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference

    GLOBENEWSWIRE

    Lisata Announces First Patient Treated in Cohort of the BOLSTER Trial of LSTA1

    GLOBENEWSWIRE

    Lisata Announces EMA Has Granted LSTA1 Orphan Drug Designation

    GLOBENEWSWIRE

    Lisata Therapeutics Announces Participation in Upcoming Conferences in October

    GLOBENEWSWIRE

    Lisata Therapeutics Announces Participation in InfoSec World 2023

    GLOBENEWSWIRE

    Lisata Therapeutics Announces First Patient Treated in BOLSTER Trial of LSTA1

    GLOBENEWSWIRE

    Lisata Announces Outcome of Futility Analysis for its Phase 2b Trial of LSTA1

    GLOBENEWSWIRE

    Lisata Therapeutics Announces Participation in Upcoming Conferences in September

    GLOBENEWSWIRE

    Lisata Therapeutics Reports Second Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Lisata Announces U.S. FDA Orphan Drug Designation Granted to LSTA1

    GLOBENEWSWIRE

    Lisata Therapeutics to Report Second Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Lisata Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors

    GLOBENEWSWIRE

    Lisata to Present at the GCFF Innovation and Healthcare Virtual Conference

    GLOBENEWSWIRE

    Lisata Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.